| Spotting hidden disease
Conventional cognitive screening tools were designed to detect established impairment, not the earliest behavioral manifestations of neurodegenerative disease. These paper-based tests showed little sensitivity to early changes, underscoring the value of digitally captured and AI-analyzed behavior. That value includes the development of the first behavioral digital biomarkers for Alzheimer’s disease that link everyday cognitive behavior with underlying pathology. The biomarkers deliver richer behavioral measurements, offering broader clinical insights from a single patient interaction. A step forward
Digital behavioral assessments offer a complementary and far more accessible first step. They are fast, noninvasive, and well-suited for primary care and community settings. More importantly, they capture dimensions of performance that clinicians cannot reliably quantify in real time. Timing between strokes, hesitation before decisions, and subtle changes in speech rhythm can become data points that human observers on their own would easily overlook or simply not be able to detect. AI enables these signals to be interpreted at scale. With machine learning models trained on datasets that pair behavioral performance with biological measures, clinicians can identify patterns aligned with early disease processes. This opens the door to earlier risk identification without relying on advanced, costly diagnostics as the first step. Patterns revealed
The convergence of behavioral science and AI creates an opportunity to make cognitive and brain health assessment routine, scalable, and actionable. A few minutes of interaction with a digital tablet and speaking can reveal patterns that once required advanced imaging, years of observation, or were just completely undetectable. — By MedCity Influencer David Bates |
%20(1).png)
No comments